Bringing precision medicine to the clinic: From genomic profiling to the power ofclinical observation

Annals of Oncology

Volumn 24, Issue 8, 2013, Pages 1956-1957

  Baselga, Jose ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BYL 719; CETUXIMAB; EVEROLIMUS; EXEMESTANE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG; VEMURAFENIB;

ACCURACY; ADVANCED CANCER; BLADDER CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOSENSITIVITY; CLINICAL EFFECTIVENESS; CLINICAL MEDICINE; CLINICAL OBSERVATION; COLON CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; GENE EXPRESSION; GENE FREQUENCY; GENOME ANALYSIS; HUMAN; LOSS OF FUNCTION MUTATION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; PRIORITY JOURNAL; SOMATIC MUTATION; THYROID CARCINOMA; TREATMENT DURATION;

GENE LIBRARY; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84881234958     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt273     Document Type: Editorial

References (16)

1. Shah SP, Roth A, Goya R et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486: 395-399.
2. Stephens PJ, Tarpey PS, Davies H et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486: 400-404.
3. Banerji S, Cibulskis K, Rangel-Escareno C et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012; 486: 405-409.
4. Ellis MJ, Ding L, Shen D et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486: 353-360.
5. Curtis C, Shah SP, Chin SF et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352.
6. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
7. Barretina J, Caponigro G, Stransky N et al. The cancer cell line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-607.
8. Garnett MJ, Edelman EJ, Heidorn SJ et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483: 570-575.
9. Wagle N, Berger MF, Davis MJ et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012; 2: 82-93.
10. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormonereceptor- positive advanced breast cancer. N Engl J Med 2012; 366: 520-529.
11. Gabriel N, Hortobagyi MJP-G, Rugo HS et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2. In ASCO Annual Meeting 2013. Chicago, IL, 2013.
12. Jose Baselga MP, Rugo H, Chen D et al. Assessment of genetic alterations using next-generation sequencing in postmenopausal women with hormone receptorpositive, HER2-negative advanced breast cancer: results from the BOLERO-2 phase III trial. In AACR Annual Meeting 2013. Washington, DC, 2013.
13. Juric D, Baselga J. Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors. J Clin Oncol 2012; 30: 765-766.
14. Dejan Juric JR, Gonzalez-Angulo AM, Burris HA, III et al. BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. In AACR Annual Meeting 2012. Chicago, IL, 2012.
15. Iyer G, Hanrahan AJ, Milowsky MI et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012; 338: 221.
16. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013 June 2 [epub ahead of print], doi: 10.1056/ NEJMoa1302369.